Avid Bioservices Inc (CDMO)

[hutschi]

This is from Nov.2017

http://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1385690


Novartis : Reports Summarize Cancer Study Results from Novartis (Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3...

01/19/2018 | 01:53am CET

Reports Summarize Cancer Study Results from Novartis (Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy)

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Investigators publish new report on Oncology - Cancer. According to news reporting from Cambridge, Massachusetts, by NewsRx journalists, research stated, "Both data in preclinical cancer models and data with T cells from patients with advanced cancer support a role for Tim-3 blockade in promoting effective anti-tumor immunity. Consequently, there is considerable interest in the clinical development of antibody-based therapeutics that target Tim-3 for cancer immunotherapy."

The news correspondents obtained a quote from the research from Novartis, "A challenge to this clinical development is the fact that several ligands for Tim-3 have been identified: galectin-9, phosphatidylserine, HMGB1, and most recently, CEACAM1. These observations raise the important question of which of these multiple receptor:ligand relationships must be blocked by an anti-Tim-3 antibody in order to achieve therapeutic efficacy. Here, we have examined the properties of anti-murine and anti-human Tim-3 antibodies that have shown functional efficacy and find that all antibodies bind to Tim-3 in a manner that interferes with Tim-3 binding to both phosphatidylserine and CEACAM1."

According to the news reporters, the research concluded: "Our data have implications for the understanding of Tim-3 biology and for the screening of anti-Tim-3 antibody candidates that will have functional properties ."

For more information on this research see: Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. Oncoimmunology, 2017;7(2):e1385690 (see also Oncology - Cancer).

Our news journalists report that additional information may be obtained by contacting C.A. Sabatos-Peyton, Exploratory Immuno-oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, United States. Additional authors for this research include J. Nevin, A. Brock, J.D. Venable, D.J. Tan, N. Kassam, F. Xu, J. Taraszka, L. Wesemann, T. Pertel, N. Acharya, M. Klapholz, Y. Etminan, X. Jiang, Y.H. Huang, R.S. Blumberg, V.K. Kuchroo and A.C Anderson.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1080/2162402X.2017.1385690. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Antibodies, Pharmaceutical Companies, Cancer, Business, Oncology, Cambridge, Immunology, Massachusetts, United States, Micronutrient, Blood Proteins, Immunoglobulins, Diet and Nutrition, Drugs and Therapies, Health and Medicine, North and Central America, Phosphatidylserine Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters



http://www.4-traders.com/NOVARTIS-9364983/news/Novartis-Reports-Summarize-Cancer-Study-Results-from-Novartis-Blockade-of-Tim-3-binding-to-phosph-25834427/